Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRON-0200 Prime and Boost Vaccination in Chronic HBV Infection
NCT06070051Phase 1Completed
- Sponsor
- Virion Therapeutics
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of VRON-0200 in Chronic Hepatitis B (CHB) (6 cohorts), sponsored by Virion Therapeutics. Primary endpoints: Treatment Emergent Adverse Events at 28 days, Grade 3 Adverse Events at 28 days and 3 more. Started Sep 2023; status: completed.
02
Drugs
VRON-0200
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06070051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070051.